Topic Listing for Optimer Pharmaceuticals

Ability Pursue Development Commercialization Pruvel Other Product Candidates Accelerated Vesting
Acceptance Access
Accrued Clinical Trial Costs Accrued Expenses
Accuracy Representations Warranties Acknowledgment
Acquire Excess 19999 Outstanding Shares Common Stock Voting Acquisition
Act Shall Mean Federal Food Drug Cosmetic Amended Activities
Addition Each Party Notify Other Action Taken Anywhere Additional Funding
Additional Indication Urinary Tract Infection Address Notices Selling Stockholder
Adjustments Administration
Advanced Biologics Advantages
Affiliate Alain Schreiber
Allegation Infringement Parties Amendment
Amendment Agreement Regarding Employment Terms Amendment Employment Agreement
Amendment Waiver Amendments Incorporation Bylaws Annual Shareholders Meeting
Amendments Waivers Annual Meeting Stockholders Held 2008
Annual Review Anthony Altig
Antibiotic Market Background Api Development Committee
Api Shall Mean Tiacumicin Active Pharmaceutical Ingredient Cas Approved Space Plan
Arbitration Asean Countries
Assignment Assignment Agreements
Assignment Form Assignment Successors
Attorneys Fees Audit Committee
Audit Committee Related Matters Audits
Auerbach Cpa Authorization
Authorization Shares Authorized Disclosure
Background Bankruptcy
Base Salary Basis Presentation
Beneficial Owner Shares Registered Name Broker Bank Other Beneficial Ownership Registrable Securities Issuable Pursuant Agreement
Beneficial Ownership Reporting Compliance Benefits Eligible Employees Less Service
Benefits Eligible Employees Service Biocon
Biocon Obligations Shall Best Commercial Efforts Ensure Api Biocon Representations Warranties Hereby Represents Warrants Par
Blocked Currency Blocon Limited
Board Directors Recommends Vote Election Each Nominees Director Broker-dealer Status
Brokers Build Branded Anti-infective Franchise Through Current In-licensed Product
Build Marketing Sales Capabilities Core Markets Business
Business Involves Hazardous Materials Third-party Manufacturers Comply Environmental Business Operations Suffer Event Computer Telecommunications Other System
Bylaws Calculation Award
Capitalization Captions Paragraph Inserted Convenience Only Way Construed Define
Cash Equivalents Investments Cash Equivalents Short-term Investments
Cash Flows Casualty Damage
Catheter-related Cause
Cautionary Regarding Forward-looking Statements Cdad Prevention
Cdi Prevention Cem-101 Op-1068 Macrolide Ketolide Antibiotics
Cempra Compulsory Licenses Cempra Know-how
Cempra Patents Cempra Pharmaceuticals
Cempra Pharmaceuticals Inc Cempra Pharmaceuticals Receives Exclusive Rights Optimer Macrolide Antibacterial
Cempra Product Cempra Representations Warranties
Cempra Sublicensing Certain Relationships Related Transactions Director Independence
Certain Remedies Certification
Certification Principal Executive Officer Certification Principal Executive Officer Pursuant 302 Sarbanes-oxley Act
Certification Principal Financial Officer Certification Principal Financial Officer Pursuant 302 Sarbanes-oxley Act
Certification Such Destruction Par Shall Receipt Biocons Request Cgmp Shall Mean Current Good Manufacturing Practices Required
Change Control Change Control Means Occurrence Following Events
Change Control Severance Arrangements Change Control Transactions
Change Vote After Submitting Proxy Changes Internal Control Over Financial Reporting
Clinical Studies Future Plans Clinical Trials Involve Lengthy Expensive Process Uncertain Outcome
Closing Clostridium Difficile Infections
Clostridium Difficile-associated Diarrhea Clostridium Difficile-infections
Code Ethics Collaboration
Collaboration Agreement Collaboration Grant Revenues
Collaborative Research Development License Agreement Combination Product
Commence Commercial Sale
Commercial Success Product Candidates Depend Attaining Significant Market Commercialization
Commitments Common Stock Issued Technology Licenses
Common Stock Market Price Common Stock Purchase Agreement
Common Stock Reserved Issuance Communications
Communications Computer Lines Comparison 2005 2004
Comparison 2006 2005 Comparison 2007 2006
Comparison 2008 2007 Comparison Cumulative Total Return
Compensation Committee Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Discussion Analysis
Compensation Other Information Concerning Executive Officers Directors Certain Completion
Comply Applicable Rules Regulations Comply Federal State Fraud Abuse Laws Unable Fully
Comprehensive Income Loss Concentration Credit Risk
Condemnation Conditions Applicable Severance Period
Conditions Obligations Conditions Precedent Closing
Conditions Purchasers Obligations Each Closing Conduct Research
Confidential Information Confidentiality Public Disclosure
Conflict Interest Conjunction Selling Goods Services
Consent Independent Registered Public Accounting Firm Construction
Constructive Termination Consummation Sale Disposition Substantially Assets
Contacts Continue Incur Significant Costs Result Operating Public Management
Continuous Marketing Application Contract Research Organization Purchase Orders
Contractual Obligations Control
Control Defense Controls Procedures
Cooperation Cordially Invited Attend Meeting Person Whether Not Expect
Corporate Highlights Corporate Power
Corporate Updates Counterparts
Counterparts Facsimile Covenants Been Read Understood Freely Accepted
Critical Accounting Policies Critical Accounting Policies Estimates
Cumulative Remedies Provided Herein Not Exclusive Other Law Current Healthcare Laws Regulations Future Legislative Regulatory Reforms
Current Report Pursuant Securities Exchange Act 1934 Current Treatments Limitations
Currently Depend Future Continue Parties Manufacture Product Candidates Currently Marketing Sales Organization Experience Drug Products Unable
Date Termination Death Disability
Death Severance Period Decision-making
Deferred Rent Delays Clinical Trials Common Causes Such Result Increased
Delays Omissions Deliverables Shall Delivered Accordance
Departure Directors Certain Officers Election Appointment Departure Directors Certain Officers Election Appointment Compensatory
Departure Directors Certain Officers Election Appointment Compensatory Arrangements Dependent Party Collaborators Unable Enter Future Collaboration Agreements
Determine Whether Enterprises Variable Interest Interests Give Controlling Develop Development
Develop Lead Product Candidates Clinical Regulatory Approval Development Commercial Supply Api Biocon Discovers Need Substantial
Development Commercialization Costs Development Committee Shall
Development Plan Reports Difficult Costly Protect Intellectual Property Proprietary Technologies Not
Difimicin Other Indications Diligent Efforts
Diligent Efforts Decision Not Develop Director Independence
Directors Directors Consultants Parent Subsidiary Corporations Employees
Directors Executive Officers Corporate Governance Disclaimer
Disclaimer Concerning Technology Disclosure
Disclosure Information Discretionary Annual Bonus
Disputes Dividends
Documents Incorporated Reference Dollars
Effects Termination Election Directors
Eligibility Employee Benefit Plan
Employee Benefit Plans Employee Benefits
Employee Proprietary Agreement Employee Stock Purchase Plan
Employees Employment Agreement
Employment Contracts Termination Change-in-control Arrangements Entire Agreement
Entire Agreement Amendment Entry Landlord
Entry Material Definitive Agreement Equity Compensation Plan Information
Equity Incentive Plan Establishment Goals
Estimates Ethical Standards
European Institute Business Administration Evaluating Investments Other-than Temporary Impairments
Evaluation Disclosure Controls Procedures Even Receive Regulatory Approval Product Candidates Subject Ongoing
Except Expressly Provided Herein Including Without Limitation Premises Except Set Forth Below Undersigned Not Beneficial Registered
Exceptions Exchange Rate
Exclusion Damages Exclusive Services
Exculpation Among Purchasers Execution Entity
Execution Individual Executive Compensation
Executive Officers Exhibits
Explanatory Fail Attract Retain Senior Management Key Scientific Personnel
Fail Develop Commercialize Other Products Product Candidates Unable Fail Gain Maintain Approval Regulatory Authorities International Markets
Fail Gain Maintain Marketing Approvals Regulatory Authorities International Fail Obtain Additional Financing Unable Commercialize Opt-80 Prulifloxacin
Fail Obtain Additional Financing Unable Complete Development Commercialization Failure Tenant Pay Rent Due Unless Such Cured
Fair Market Value Fair Value Financial Instruments
Fast Track Products Designation Fda
Fda Approval Process Fidaxomicin Other Indications
Financial Guidance Financial Operations Overview
Financial Results Financial Statements Exhibits
Financing Agreement Find Out Results Voting Annual Meeting
Finders Fee Force Majeure
Forecasts Orders Par Shall Provide Purchase Biocon Api Foreign Currency Translation
Foreign Exchange Form 10-q
Form Irrevocable Transfer Agent Instructions Forward-looking Statements
François-xavier Frapaise Fte
Funding Requirements Further Actions
Future Accounting Requirements Future Growth Depends Ability Identify Acquire In-license Products
Future Product Candidates Rights International Markets Market Opportunities Future Sales Common Stock Public Market Cause Price
General General Administrative Expense
General Principles General Representations Warranties
Glycooptimization Goal Achievement Percentage
Good Clinical Practices Gcp Good Laboratory Practices Glp
Good Manufacturing Practices Gmp Governing Law
Governing Law Arbitration Governing Law Venue
Governmental Authority Grant Revenues
Gratuities Hatch-waxman Act
Headings Held 2008
Held 2009 Hierarchy Generally Accepted Accounting Principles Replacement Fasb Statement
Holdover Householding Proxy Materials
Howard Lee Phd Http Wwwamstockcom Proxyservices Viewmaterialaspconumber15221
Human Clinical Trial I-corporate Offices
Iii-directors Impairment Long-lived Assets
Implied Licenses Inc Research
Incentive Compensation Plan Income Taxes
Incur Significant Increased Costs Result Operating Public Management Incur Substantial Costs Result Litigation Other Proceedings Relating
Ind Indemnification
Indemnification Insurance Indemnification Obi
Indemnification Optimer Independence
Independence Board Directors Independent Contractors
Index Index Consolidated Financial Statements
Infectious Diarrhea Information
Information Exchange Infringement
Infringement Party Rights Initial Public Offering
Injunction Intellectual Property
Intellectual Property Assignment License Agreement Interest
Interest Income Expense Other Net Interest Income Other Net
Internal Control Over Financial Reporting Invention
Investor Information Investors Information
Iv-committees Ix-general Matters
John Prunty Cpa Joint Steering Committee
Joseph Chang Phd Joseph Chow
Kevin Poulos Key-employee Covenants
Know-how Landlord Exculpation
Landlords Property Leases
Legend Length Service Eligibility Partial-year Participation
Lesser Degree Other Lead Product Candidate Prulifloxacin Lesser Degree Other Lead Product Candidate Pruvel
Leverage Internal Discovery Capabilities Expertise Carbohydrate Chemistry Expand License Agreement
License Agreement Obligations License Cempra
Licensed Patents Liens
Limitation Liability Limitations
Limitations Notwithstanding Anything Contrary Herein Limited Sources Revenue Largely Dependent Success Lead Product
Liquidity Capital Resources Litigation
Long-term Incentive Compensation Long-term Incentive Program
Losses Macrolide Antibiotics
Macrolide Patent Estate Managements Discussion Analysis Financial Condition Results Operations
Managements Report Internal Control Over Financial Reporting Manufacture Supply
Manufacturing Market Opportunity
Market Price Common Stock Highly Volatile Market Registrants Common Equity Related Stockholder Matters Issuer
Marketing Marketing Expense
Marketing Sales Martin Muenchbach Phd
Meetings Meetings Board Directors
Membership Memorial Sloan-kettering Cancer Center
Methicillin-resistant Staphylococci Mrs Infections Methicillin-resistant Staphylococci Mrs Prophylaxis
Michael Chang Phd Milestone
Milestone Payment Milestone Payment Terms
Milestone Payments Cempra Milestone Payments Optimer
Milestones Minimum Achievement Level
Miscellaneous Mskcc Agreement
Mutual Indemnification Mutual Termination Rights
Name Nasal Carriage
Nasdaq Biotechnology Index Nda
Nda Means New Drug Application Pursuant Usc §355 Need Increase Size Organization Experience Difficulties Managing Growth
Negative Conditions Global Credit Markets Impair Liquidity Portion Net Loss Per Share
Net Loss Per Share Attributable Common Stockholders Net Operating Losses Tax Credit Carryforwards
Net Sales Next Page Signature
Nih Small Business Innovation Research Award Nih Small Business Innovation Research Awards
Nippon Shinyaku Nippon Shinyaku Ltd
Nominating Corporate Governance Committee Non-gaap Financial Measures
Non-solicitation Non-waiver
Nonqualified Deferred Compensation Nonwaiver
Not Able Adequately Build Own Marketing Sales Capabilities Not Able Enter Acceptable Agreements Market Commercialize
Not Able Enter Acceptable Agreements Market Commercialize Opt-80 Not Find Collaborators Future Product Candidates Required Reduce
Notice Notices
Notification Novo Glycosylation
Now Therefore Number 001-33291
Obi Opt-822 821 Technology Obi Opt-88 Technology
Objectives Philosophy Executive Compensation Offering Periods
On-going Clinical Development Next Steps Only Jury-waiver Provisions 257 Lease Not Enforceable California
Oof Principle Trial Opops Drug Discovery Platform
Opt-1068 Cem-101 Macrolide Ketolide Antibiotics Opt-1068 Opt-1273 Macrolide Ketolide Antibiotics
Opt-80 Other Indications Opt-822 821
Opt-822 821 Patents Opt-822 821 Product
Opt-88 Opt-88 Patents
Opt-88 Product Optimer
Optimer 2007 Current Highlights Optimer 2008 Recent Highlights
Optimer Announces 359 Private Placement Optimer Compulsory Licenses
Optimer Highlights Optimer Improvements
Optimer Information Optimer Know-how
Optimer Patents Optimer Pharmaceuticals
Optimer Pharmaceuticals Inc Optimer Pharmaceuticals Inc Common Stock Purchase Agreement
Optimer Pharmaceuticals Inc Form 10-q Quarterly Period 2008 Optimer Pharmaceuticals Inc Form 10-q Quarterly Period 2009
Optimer Pharmaceuticals Raise 122 Registered Direct Offering Optimer Pharmaceuticals Raise 329 Registered Direct Offering
Optimer Pharmaceuticals Regains North American Rights Difimicin Optimer Pharmaceuticals Reports 2007 Financial Results
Optimer Pharmaceuticals Reports 2007 Financial Results Including Payment Optimer Pharmaceuticals Reports 2008 Financial Results
Optimer Pharmaceuticals Reports 2009 Financial Results Optimer Pharmaceuticals Reports Full 2007 Financial Results
Optimer Pharmaceuticals Reports Full 2008 Financial Results Optimer Product
Optimer Representations Warranties Optimer Rights Asean Countries
Optimer Sublicensing Option Exercises Stock Vested End
Oral Suspension Formulation Development Organization Business Activities
Organization Summary Significant Accounting Policies Other Collaborative Agreements
Other Compensation Other Events
Other Information Other Matters
Other Pipeline Product Candidates Other Rights
Outline Premises Outside North America Needed Adequately Build Own Marketing
Overview Par Pharmaceutical Inc
Par Pharmaceuticals Inc Par Representations Convents Warranties Hereby Represents Warrants Biocon
Parking Part
Part Cautionary Regarding Forward-looking Statements Participation Initial Public Offering
Participation Private Placement Participation Registered Direct Offerings
Parties Mutually Agree Follows Party
Party Commercialization Party Royalties Cempra Products
Party Royalties Optimer Products Patent
Patent Enforcement Patent Prosecution
Patent Prosecution Maintenance Cempra Patents Patent Prosecution Maintenance Optimer Patents
Patent Prosecution Maintenance Patents Claiming Other Joint Inventions Patents
Paying Proxy Solicitation Payment Method
Payment Reports Payments Payment Reports
Pension Benefits Performance
Performance Measurement Comparison Performance Units Shares
Peter Grebow Phd Phase
Phase Clinical Trial Phase Clinical Trials
Phase Pivotal Trials Phase Studies
Phase Study Phase Trial
Phase Trials Plan
Plan Amendments Termination Plan Distribution
Plan Governance Plans
Please Detach Here Please Fax Copy Completed Executed Notice Questionnaire Return
Potential Difimicin Advantages Potential Opt-80 Advantages
Power Pre-approval Policies Procedures
Pre-clinical Clinical Supply Pre-clinical Development
Pre-clinical Studies Future Plans Preclinical Testing Human Clinical
Press Release Prevention Nosocomial Vancomycin-resistant Enterococci Vre Bloodstream Infections
Prevention Nosocomial Vre Bloodstream Infections Prevention Vre Cdi
Price Payments Pricing
Principal Accountant Fees Services Principal Accounting Fees Services
Principal Stockholders Management Own Significant Percentage Stock Able Principles Consolidation
Private Placement Procedure
Proceeds Sale Registered Securities Product Candidates Unable Compete Effectively Branded Generic Antibiotics
Product Complaints Recalls Product Development
Product Liability Lawsuits Brought Against Incur Substantial Liabilities Product Liability Lawsuits Successfully Brought Against Incur Substantial
Product Resale Pronouns
Properties Property Equipment
Proposed Phase Marketing Support Trial Proposed Transferee Affiliates Date Transfer Notice Received Leases
Provides Update Product Development Programs Proxy Card Valid Only Signed Dated
Proxy Solicited Board Directors Annual Meeting Stockholders Held Prulifloxacin Develop Commercialize Other Product Candidates Continue Research
Prulifloxacin Manufacturers Fail Provide Collaborators Adequate Supplies Clinical Pruvel Develop Commercialize Other Product Candidates Continue Research
Pruvel Manufacturers Fail Provide Collaborators Adequate Supplies Clinical Public Offering
Publications Publicity
Purchase Orders Forecasts Delivery Purchase Price Par Shall Pay Biocon Api Per
Purchase Shares Pursuant 302 Sarbanes-oxley Act 2002
Qualified Change Control Means Occurrence Following Events Quantitative Qualitative Disclosures Market Risk
Ratification Selection Independent Auditors Receivable Officer
Receiving Materials Recent Accounting Pronouncements
Recent Corporate Highlights Recent Highlights
Recent Proposed Legislation Permit Re-importation Drugs Foreign Countries Recent Sales Unregistered Securities
Recently Adopted Accounting Pronouncements Recently Adopted Guidance
Recently Issued Accounting Pronouncements Recitals
Records Audits Redeemable Convertible Preferred Stock
Redeemable Convertible Preferred Stock Series Regarding Non-gaap Financial Measures
Registration Registration Procedures
Regulatory Approval Regulatory Authority
Regulatory Filing Regulatory Matters
Reimbursement Reimbursement Expenses
Related Party Transactions Relationships
Rely Parties Conduct Clinical Trials Not Successfully Carry Remainder Page Intentionally Left Blank
Renew Respective Existing Insurance Coverage Such Expires Obtain Rent
Report Audit Committee Board Directors Report Independent Registered Public Accounting Firm
Representations Warranties Representations Warranties Investor
Representations Warranties Purchasers Repurchases Equity Securities
Required Suspend Discontinue Clinical Trials Due Adverse Events Research Development
Research Development Expense Research Development Expenses
Research Program Research Supply Costs
Research Term Reserved
Restricted Cash Restricted Stock Awards
Restricted Stock Units Results Operations
Results Operations Financial Condition Revenue Other Collaborative Agreements
Revenue Recognition Revenues Collaborative Research Agreements
Revenues Research Grants Reverse Stock Split
Reversion Assignments License Obi Technology Rights Bankruptcy
Royalties Cempra Royalty Payments
Royalty Payments Optimer Royalty Term
Sale Issuance Common Stock Sale Issuance Units
Sale Purchase Sale Purchase Api
San Diego 2007- San Diego 92121
Schedule Stockholders Scheduled Conference Call
Scripps Agreement Scripps Research Institute
Securities Authorized Issuance Equity Compensation Plans Securities Purchase Agreement
Securities Registered Pursuant Act Security Deposit
Security Ownership Certain Beneficial Owners Management Related Stockholder Selling Stockholder Notice Questionnaire
Settlement Such Claims Shall Settled Other Party Defending Severability
Severance Severance Benefit Plan
Share Reserve Sherwood Gorbach
Signature Signature Page Investor Follows
Signatures Signatures Following Page
Signed Dated Sloan-kettering Institute Cancer Research
Some Provisions Charter Documents Delaware Law Anti-takeover Effects Sorrento Valley Road Suite San Diego 92121
Sorrento Valley Road Suite San Diego 92121 Address Sources Liquidity
Stock Appreciation Rights Stock Appreciation Rights Restricted Units
Stock Awards Stock Option Grants Awards Executive Officers
Stock Option Grants Executive Officers Stock Options
Stock Options Purchase Rights Stock Plan
Stock Plans Stock Purchase Agreement
Stock Split Stock-based Compensation
Stockholder Communications Board Directors Stockholder Director Recommendations
Stockholder Proposals Due Next Annual Meeting Stockholder Record Shares Registered Name
Stockholders Agreement Stockholders Equity
Strategy Strict Construction
Sublicenses Sublicensing Revenue
Submission Matters Vote Security Holders Subordination Estoppel Certificates
Subscription Agreement Subsequent Event
Subsequent Events Subsidiaries
Successors Assigns Summary Significant Accounting Policies
Supply Agreement Surrender
Survival Synthesis Macrolide Antibiotics Biological Testing
Table Contents Taxes
Technology Tenant Becomes Breach 253
Term Term Employment
Term Office Term Termination
Termination Termination Agreement Shall Not Been Terminated Such Purchaser
Termination Cempra Optimer Termination Employment
Termination Mutual Agreement Terminated Written Parties Termination Plan
Termination Prior License Agreement Forgiveness Loans Termination Revocation
Terms Agreement Terms Proposed Transfer Including Effective Date
Territory Tessie Che Phd
Test Product Third-party Payor Coverage Reimbursement Insufficient Unavailable Altogether Product
Titles Subtitles Total Revenues
Trademarks Transactions Related Persons
Transfer Shares Transferability
Transferability Awards Treasury Shares
Treasury Stock Treatment Confidential Information
Unable Obtain Fda Approval Product Candidates Not Able Undersigned Reviewed Form Plan Distribution Attached Annex Registration
Understand Agree Completely Terms Set Forth Optimer Pharmaceuticals Unit Purchase Agreement
United States Dollars Unless Contrary Direction Indicated Proxy Voted Nominees Listed
Unregistered Sales Equity Securities Unregistered Sales Equity Securities Proceeds
Upcoming Conferences Upfront Payment
Used Future Research Development Activities V-officers
Valid Claim Value Received
Vi-stock Vii-manner Giving Notice Waiver
Viii-indemnification Vote
Vote Annual Meeting Vote Mail
Votes Votes Counted
Votes Needed Approve Each Proposal Voting Shares
Waiver Waiver Breach Severability
Waiver Conflicts Warrant
Warrants What Broker Non-votes
What Mean Receive Proxy Card What Quorum Requirement
What Return Proxy Card Not Make Specific Choices What Voting
Whereas Whereas Biocon Desires Supply Par Requirements Active Pharmaceutical
Withholding Witness Whereof
Witnesseth Work Letter
Work Performed Date Work Plan Budget
Work Product X-amendments
Youe-kong Shue Phd 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki